Welcome to our dedicated page for Werewolf Therapeutics SEC filings (Ticker: HOWL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Werewolf Therapeutics SEC filings document material events, operating results, governance matters, and capital-structure disclosures for a Delaware biopharmaceutical company developing conditionally activated immune therapeutics. Recent 8-K filings furnish quarterly financial results, press-release exhibits, and updates tied to the company’s PREDATOR, INDUKINE, and INDUCER programs.
The filings also cover Nasdaq continued-listing matters, audit committee composition, exit and disposal activities, emerging growth company status, common stock registered under the HOWL symbol, shareholder voting matters, clinical and regulatory disclosures, and risk language related to strategy, operations, development plans, and corporate alternatives.
RA Capital Management and affiliated funds report beneficial ownership of 6,116,140 shares of Werewolf Therapeutics common stock, equal to 12.6% of the company, based on 48,596,817 shares outstanding as of May 1, 2026. Most of these shares, 5,709,858 or 11.7% of the class, are held by RA Capital Healthcare Fund, with the balance held by RA Capital Nexus Fund II. RA Capital has delegated voting and investment authority over the funds’ holdings and may be deemed a beneficial owner for Section 13(d) purposes, while the funds themselves disclaim beneficial ownership. The amendment also details recent open market sales by the Fund and Nexus Fund II from May 8 to May 12, 2026 at weighted average prices between $0.64 and $0.71 per share, and notes that the reported ownership percentages reflect an increase in the issuer’s outstanding shares.
Werewolf Therapeutics director-affiliated entities reported an open-market sale of company stock. Entities associated with Luke Evnin sold 44,679 shares of Werewolf Therapeutics common stock at a weighted average price of $0.54 per share in an open-market transaction. The sale was executed on May 13, 2026 under a pre-arranged Rule 10b5-1 trading plan dated March 26, 2026. After this transaction, these entities collectively held 1,126,496 shares indirectly, allocated among several MPM investment vehicles. Evnin disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
Werewolf Therapeutics’ major MPM-affiliated investors filed Amendment No. 7 to Schedule 13D updating their ownership in the company’s common stock. The filing shows various MPM funds and related entities holding individual stakes ranging from 0.1% to 3.8% of outstanding shares.
As of May 1, 2026, the ownership percentages are calculated against 48,596,817 shares of Werewolf Therapeutics common stock. The reporting group sold blocks of shares in open-market transactions between May 6 and May 12, 2026 at average prices generally around $0.63–$0.70 per share.
Werewolf Therapeutics, Inc. director-associated investment entities reported open-market sales of an aggregate 407,574 shares of Common Stock in three transactions. The sales occurred on May 8, May 11, and May 12 at weighted average prices of $0.70, $0.67, and $0.64 per share, respectively. After these transactions, entities associated with Luke Evnin collectively held 1,171,175 shares indirectly. The filing notes the trades were effected under a pre-established Rule 10b5-1 trading plan, indicating they were pre-planned rather than discretionary.
Werewolf Therapeutics, Inc. insider affiliates of RA Capital reported open-market sales of an aggregate 565,167 shares of Common Stock of HOWL. The trades occurred on May 8, 11 and 12, 2026 at weighted average prices around $0.64 per share, with detailed ranges from $0.62 to $0.76 disclosed.
The shares were sold indirectly through RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund II, L.P., with RA Capital Management, L.P. acting as investment manager. Following the latest transactions, one account held 406,282 shares and another held 5,709,858 shares of Common Stock indirectly. The Adviser, its general partner and related individuals disclaim beneficial ownership except to the extent of any pecuniary interest.